Fig 3. The absence of SV2A protein in the hippocampus does not lower the epileptic threshold.

A: Western blot analyses revealing SV2A protein depletion in the hippocampus of Grik4:SV2A-cKO mice in comparison with that of WTs. A’: Quantification of the SV2A proteins extracted from the hippocampus of WT and Grik4:SV2A-cKO mice (n = 3/group, data presented as mean ± SEM, ***p <0,001). B: Western blot analyses demonstrating SV2A protein depletion in the cerebral cortex and CA3 of Grik4:SV2A-cKO mice compared to WT. B’: Quantification of the SV2A proteins (n = 3/group, data presented as mean ± SEM, ***p <0,001). C: Conditional removal of SV2A from adult mice CA3 areas validated by using in vitro autoradiography with the radioligand ¹⁸F-UCB-H (scale bar = 500μm). D: Semi-quantitation of ¹⁸F-UCB-H signal intensity in the hippocampus (ROD: radioluminescence optical density). E: Number of seizures per animal in those expressing different behavioral categories post-PTZ injection: sudden behavioral arrest (Stage 1), facial jerking (Stage 2), neck jerks (Stage 3), clonic seizures (sitting) (Stage 4), tonic seizure (lying on belly) (Stage 5), tonic seizure with wild jumping (Stage 6).